Many components of mitogenic signaling pathways in normal and neoplastic cells have
been identified, including the large family of protein kinases, which function as components …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from the
clonal expansion of a transformed multipotent hematopoietic stem cell. CML is a biphasic …

Constitutive overexpression and activation of NPM-ALK fusion protein [t (2: 5)(p23; q35)] is a
key oncogenic event that drives the survival and proliferation of anaplastic large-cell …

The chimeric BCR–ABL oncoprotein is the molecular hallmark of chronic myelogenous
leukemia (CML). BCR–ABL contains nuclear import and export signals but it is localized …

The adaptor protein Lnk, and the closely related proteins APS and SH2B, form a subfamily of
SH2 domain-containing proteins implicated in growth factor, cytokine, and immunoreceptor …

Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell
transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic …

The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced
cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I …

Chronic myelogenous leukemia (CML) is defined by the presence of the Philadelphia (Ph)
chromosome, which results in the expression of the 210 kDa Bcr–Abl tyrosine kinase. Bcr …

Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL
tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In …